R&D (research and development) sector & industry count cost of Parliament stem cell objections
This article was originally published in Clinica
Executive Summary
The EU medical research community was put in a spin when the European Parliament voted at its session on April 9-10 to add series of amendments to the Commission's proposed directive on the safe sourcing of human tissues and cells. The delay represents a new hurdle for the medical devices industry, which is a regular user of human tissues and cells in products such as heart valves, vascular grafts and dermal replacements